Specialist pharmacy BioMatrix SpRx revealed on Wednesday the completion of the acquisition of Elwyn Pharmacy Group for undisclosed amount.
Located in Garnet Valley, Pennsylvania, southwest of Philadelphia, Elwyn Pharmacy Group provides a complete range of specialty pharmacy and infusion services. It treats a wide array of complex disease states including Multiple Sclerosis, Hepatitis C and other GI related diseases, Oncology/Cancer, bleeding disorders, Rheumatoid Arthritis, Psoriasis and HIV. The Elwyn Pharmacy Group includes Elwyn Pharmacy, Glen Rock Medical Pharmacy, Elwyn Specialty Care, and Med Center Specialty Pharmacy.
With this acquisition, BioMatrix has expanded their services into complementary therapeutic categories requiring the same high-touch services they are accustomed to providing. The company has doubled its company size as well as added therapeutic categories to portfolio of services.
Upon closing, BioMatrix's national footprint increases to 11 pharmacy locations, nationwide, in key metropolitan locations. Elwyn joins the rapidly growing family of companies that comprise BioMatrix including Matrix Health Group, Factor Support Network, Medex BioCare, and BiologicTx.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007